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Abstract 
Introduction: Infections caused by multiple drug-resistant pathogens represent an increasingly often encountered challenge in 
clinical practice. The problem particularly applies to patients with chronic lung diseases resulting in multiple hospitalisations. The 
aim of this paper was to analyse the incidence of alert pathogens isolated from patients hospitalised in the department of lung 
diseases, who were divided into three groups: patients qualified for lung transplantation, patients treated for neoplastic diseases 
and patients with chronic lung diseases.
Materials and methods: Analysis involved microbiological test results of 3950 samples obtained from 3521 patients divided 
into: 200 patients being qualified for lung transplantation, 1292 patients treated for neoplastic diseases and 2029 patients with 
chronic lung diseases.
Results: Infection with alert pathogen was found in 155 of 3521 patients (4.4%). Most often isolated infectious agent was 
P. aeruginosa, which accounted for 27% of infections. Other pathogens were as follows A. baumanii ESBL(−) (13%), S. pneumoni-
ae (12%), E. cloacae ESBL(+) (10%), K. pneumoniae ESBL(+) (10%), S. aureus MRSA (8%), E. faecalis (7%), E. coli ESBL(+) (6%), 
S. maltophilia ESBL(+) (5%) and E. kobei ESBL(+) (2%). Alert pathogens were found in 31 (15%) of 200 patients being qualified for 
lung transplantation, 89 (4.4%) of 2029 patients with chronic lung diseases and 35 (2.7%) of 1292 patients treated for neoplastic 
diseases. Difference between infection frequency in patients being qualified for lung transplantation and the remaining groups was 
statistically significant (p < 0.01). P. aeruginosa infection was the most frequent in all groups. It constituted 35% in patients being 
qualified for lung transplantation, 29% in patients treated for neoplastic diseases and 22% in patients with chronic lung diseases. 
Conclusions: Infections caused by alert pathogens were found in more than 4% of patients hospitalised in the department of lung 
diseases between 2007 and 2011. Their frequency was significantly higher in patients being qualified for lung transplantation than 
in other analysed groups. In all examined groups the most frequently isolated bacteria was P. aeruginosa (27% of all isolates).
Key words: alert pathogens, lung diseases, antibiotic resistance, lung transplantation, lung cancer
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Streszczenie
Wstęp: Zakażenia spowodowane przez patogeny wielolekooporne stają się coraz częściej wyzwaniem terapeutycznym dla 
klinicystów. Problem ten dotyczy również pacjentów z przewlekłymi chorobami płuc wymagających wielokrotnych hospitalizacji. 
Celem pracy była analiza częstości występowania patogenów alarmowych wyizolowanych od chorych oddziału chorób płuc, 
w podziale na trzy grupy: kwalifikowanych do przeszczepienia płuca, leczonych z powodu choroby nowotworowej oraz leczonych 
z powodu przewlekłych chorób płuc. 
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Materiał i metody: Analiza dotyczyła wyników badań mikrobiologicznych 3950 materiałów pochodzących od 3521 chorych: 
w tym 200 chorych — kwalifikowanych do przeszczepienia płuca, 1292 — leczonych z powodu choroby nowotworowej i 2029 
— leczonych z powodu przewlekłej choroby płuc. 
Wyniki: Zakażenia patogenem alarmowym stwierdzono u 155 spośród 3521 chorych (4.4%). Najczęściej izolowanym czynnikiem 
infekcyjnym był P. aeruginosa, który stanowił 27% wszystkich zakażeń, kolejno to A. Baumanii ESBL(−) (13%), S. pneumoniae 
(12%), E. cloacae ESBL(+) (10%), K. pneumoniae ESBL(+) (10%), S. aureus MRSA (8%), E. faecalis (7%), E. coli ESBL(+) 
(6%), S. maltophilia ESBL(+) (5%) i E. kobei ESBL(+) (2%). Patogeny alarmowe stwierdzono u 31 (15%) spośród 200 chorych 
kwalifikowanych do przeszczepienia płuc, 89 (4,4%) spośród 2029 chorych na przewlekłe choroby płuc i 35 (2.7%) spośród 1292 
chorych leczonych z powodu choroby nowotworowej. Różnica pomiędzy częstością zakażeń w grupie chorych kwalifikowanych 
do przeszczepienia a pozostałymi grupami chorych była istotna statystycznie (p < 0.01). We wszystkich grupach chorych domi-
nowało zakażenia P. aeruginosa. Stanowiło ono: w grupie chorych kwalifikowanych do przeszczepienia — 35%, w grupie chorych 
leczonych z powodu nowotworu — 29%, w grupie chorych z przewlekłą chorobą płuc — 22%. 
Wnioski: Zakażenie bakteriami alarmowymi dotyczyło ponad 4% chorych hospitalizowanych na oddziale chorób płuc w latach 
2007−2011. Występowało ono istotnie częściej u chorych kwalifikowanych do przeszczepienia płuc niż w pozostałych dwóch 
grupach analizowanych chorych. We wszystkich grupach najczęściej izolowaną bakterią alarmową była pałeczka ropy błękitnej 
(27% wszystkich zakażeń). 
Słowa kluczowe: patogeny alarmowe, choroby płuc, antybiotykooporność, przeszczepienie płuca, rak płuca
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Introduction
Infections caused by drug-resistant bac-
terial strains constitute a  significant problem 
in patients hospitalised in the pulmonology 
departments. The necessity of frequent use of 
antibiotics and chemotherapeutic drugs in this 
group of patients increases resistance of micro-
organisms to the used drugs and consequently, 
leads to the appearance of multidrug-resistant 
strains [1−3]. Furthermore, it should be em-
phasised that there are more and more people 
with reduced resistance, who are exposed to 
infectious complications. It is related to an in-
creased number of older patients with chronic 
diseases, who undergo lung transplantation and 
cytostatic treatment [4, 5]. Drug resistance of 
bacterial strains contributes to limited thera-
peutic possibilities, prolonged hospitalisations 
and consequently, a higher probability of failure 
of the applied treatment [5–8], and a  consid-
erable increase in hospitalisation costs [8, 9]. 
Supervisory programmes that control infections 
with alert pathogens focus on rapid methods 
of pathogens identification, implementation 
of correct procedures for the patient isolation 
and preparation of specialised therapeutic al-
gorithms [5, 7, 10]. 
The aim of the study was to analyse the 
prevalence of alert pathogens isolated from pa-
tients of the department of lung diseases divided 
into three groups: patients qualified for lung 
transplantation, patients treated for neoplastic 
diseases and patients treated for chronic lung 
diseases.  
Material and methods
3950 clinical specimens were analysed (85% 
sputum, 3% urine, 2% blood) from 3521 patients 
of the pulmonology department, the Third Inde-
pendent Public Teaching Hospital in Zabrze-Bi-
skupice, hospitalised between 2007−2011. 
Basing on clinical characteristics, patients 
were divided into three groups:
— patients qualified for lung transplantation,
— patients treated for neoplastic lung diseases,
— patients treated for chronic lung diseases.
Microbiological diagnosis was conducted bas-
ing on applicable standards, collected material was 
cultured on proper solid or liquid media with their 
consecutive identification in semi-automatic system 
manufactured by BioMerieux Polska-Vitek; tests 
for drug resistance and identification of resistance 
mechanisms were carried out basing on standards 
defined in the guidelines of the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST).
200 specimens from the patients qualified for 
lung transplantation (5.7% of all specimens), 1292 
specimens from patients with neoplasms (36.7% 
of all specimens) and 2029 from patients with 
chronic lung diseases (57.6% of all specimens).
The obtained data were analysed statistically. 
The significance of proportion differences was 
examined using z test. Significance of differences 
between the results was assumed at p < 0.05.
Results
During the analysed 5-year period 155 drug- 
-resistant bacterial strains were isolated. In all 
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groups of patients, most frequently isolated 
pathogen was P. aeruginosa, which accounted 
for 27% of all infections. Other pathogens in ac-
cordance with their prevalence were as follows: 
A. baumanii ESBL(−) (13%), S. pneumoniae (12%), 
E. cloacae ESBL(+) (10%), K. pneumoniae ESBL(+) 
(10%), S. aureus MRSA (8%), E. faecalis (7%), 
E. coli ESBL(+) (6%), S. maltophilia ESBL(+) (5%) 
and E. kobei ESBL(+) (2%). The results of analy-
sis of the prevalence of particular strains during 
a 5-year period were presented in Figure 1.
Patients qualified for lung transplantation
In this group, the results of microbiological 
tests of 200 patients were analysed. Infection with 
resistant pathogen was diagnosed in 31 subjects 
(15.5%). 6 strains were identified: P. aerugino-
sa, A. baumanii ESBL(−), E. cloacae ESBL(+), 
K. pneumoniae ESBL(+), S. aureus MRSA and 
E. kobei ESBL(+). Among the isolated strains, most 
frequently were found: P. aeruginosa (35.5%), 
then Gram (−) bacilli: A. baumanii ESBL(−) — the 
strain that does not produce beta lactamases, with 
a wide substrate spectrum (29% of all isolates), 
the third pathogen was methicillin-resistant 
Staphylococcus aureus (MRSA), which made 
up over 16% of all isolated bacteria in the group 
(Table 1). The proportion of fermenting bacilli 
from the Enterobacteriacae did not exceed 20%, 
and most frequently isolated was K. pneumoniae 
ESBL(+), which constituted nearly 10% of all 
isolates in the group.
Patients treated for lung neoplasms
In the group of 1292 patients treated for lung 
neoplasms, 35 alert pathogens were isolated (2.7%). 
Except for bacteria mentioned in the previous 
group of patients, there were also resistant strains of 
E. coli ESBL(+) and Gram (+) cocci, i.e. E. faecalis 
and S. pneumoniae (Table 2). Similarly as in the 
first analysed group, the most frequent pathogen 
was P. aeruginosa, which was isolated from 28.6% 
of specimens. The proportion of fermenting bacilli 
from the Enterobacteriacae family was distinctly 
larger and it exceeded 31%, the most often isolated 
was Enterobacter cloacae ESBL(+), which consti-
tuted 14% of all isolates in the group. It should 
be emphasised that the proportion of Gram (+) 
cocci, including the proportion of pneumococci 
— S. pneumoniae, which is sensitive to penicillins, 
was clearly higher, compared to the previous group 
(1/3 of all isolated bacteria) and accounted for 14%. 
The proportion of MRSA was lower (8.5%).
Patients treated for chronic diseases  
of the respiratory system
In the group of patients treated for chronic 
diseases of the respiratory system, in 89 (4.4%) 
subjects out of 2029 hospitalised patients, at least 
one alert pathogen was isolated. In this group of 
patients, diverse species of isolated pathogens 
were found, with dominant P. aeruginosa, which 
was an aetiological factor of more than every fifth 
infection (22.5%), and S. pneumoniae, which is 
sensitive to penicillins (14.6%) (Table 3). The 
Rycina 1. Frequency of the particular bacterial strain isolates in the 5-year period (2007−2012) 
Pneumonologia i Alergologia Polska 2015, vol. 83, no. 2, pages 101–108 
104 www.pneumonologia.viamedica.pl
Ta
bl
e 
1.
 P
at
ie
nt
s 
qu
al
ifi
ed
 fo
r l
un
g 
tr
an
sp
la
nt
at
io
n 
(n
 =
 2
00
 S
PE
CI
M
EN
S)
Th
e 
na
m
e 
of
 th
e 
st
ra
in
20
07
 
n 
=
 5
5
20
08
 
n 
=
 4
9
20
09
 
n 
=
 3
7
20
10
 
n 
=
 3
0
20
11
 
n 
=
 2
9
To
ta
l
(p
er
ce
nt
ag
e)
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
 
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
 N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
 N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
Ps
eu
do
m
on
as
 a
er
ug
in
os
a
1
4.
30
%
3
12
.5
0
3
7.
14
2
5.
40
2
6.
89
11
35
.4
8
Ac
in
et
ob
ac
te
r b
au
m
an
ii 
ES
BL
(–
)
4
17
.4
0%
2
8.
30
1
2.
38
1
2.
7
1
3.
44
9
29
  
St
re
pt
oc
oc
cu
s 
pn
eu
m
on
ia
e
−
−
−
−
−
−
−
−
−
−
−
−
En
te
ro
ba
ct
er
 c
lo
ac
ae
 
ES
BL
(+
)
−
−
1
4.
20
−
−
1
2.
70
−
−
2
6.
45
Kl
eb
si
el
la
 p
ne
um
on
ia
e 
ES
BL
(+
)
−
−
1
4.
20
2
4.
76
−
−
−
−
3
9.
68
St
ap
hy
lo
co
cc
us
 a
ur
eu
s 
M
RS
A
−
−
1
4.
20
1
2.
38
2
5.
40
1
3.
44
5
16
.1
3
En
te
ro
co
cc
us
 fa
ec
al
is
 
−
−
−
−
−
−
−
−
−
−
−
−
Es
ch
er
ic
hi
a 
co
li 
ES
BL
(+
)
−
−
−
−
−
−
−
−
−
−
−
−
St
en
ot
ro
ph
om
on
as
 m
al
to
-
ph
ili
a 
ES
BL
(+
)
−
−
−
−
−
−
−
−
−
−
−
−
En
te
ro
ba
ct
er
 k
ob
ei
 
ES
BL
(+
)
−
−
−
−
−
−
−
−
1
3.
44
1
3.
23
En
tro
ba
ct
er
 a
er
og
en
es
 
ES
BL
(+
)
−
−
−
−
−
−
−
−
−
−
−
−
Michał Zieliński et al., Occurrence of alert pathogens in patients hospitalised in the department of lung diseases
105www.pneumonologia.viamedica.pl
Ta
bl
e 
2.
 P
at
ie
nt
s 
tr
ea
te
d 
fo
r l
un
g 
ne
op
la
sm
 (n
 =
 1
29
2 
SP
EC
IM
EN
S)
Th
e 
na
m
e 
of
 th
e 
st
ra
in
20
07
 
n 
=
 2
25
20
08
 
n 
=
 2
67
20
09
 
n 
=
 2
88
20
10
 
n 
=
 2
53
20
11
 
n 
=
 2
59
 T
ot
al
(p
er
ce
nt
ag
e)
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
 N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
 N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
 N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
Ps
eu
do
m
on
as
 a
er
ug
in
os
a
2
8.
70
4
16
.6
0
2
4.
76
2
5.
40
−
−
10
28
.6
Ac
in
et
ob
ac
te
r b
au
m
an
ii 
ES
BL
(−
)
2
8.
70
1
4.
20
−
−
−
−
−
−
3
8.
57
St
re
pt
oc
oc
cu
s 
pn
eu
m
on
ia
e
1
4.
30
1
4.
20
1
2.
38
1
2.
70
1
3.
44
5
14
.2
9
En
te
ro
ba
ct
er
 c
lo
ac
ae
 
ES
BL
(+
)
−
−
1
4.
20
1
2.
38
3
8.
10
−
−
5
14
.2
9
Kl
eb
si
el
la
 p
ne
um
on
ia
e 
ES
BL
(+
)
−
−
2
8.
30
1
2.
38
−
−
1
3.
44
4
11
.4
3
St
ap
hy
lo
co
cc
us
 a
ur
eu
s 
M
RS
A
1
4.
30
−
−
−
−
1
2.
70
1
3.
44
3
8.
57
En
te
ro
co
cc
us
 fa
ec
al
is
 
1
4.
30
−
−
−
−
1
2.
70
1
3.
44
3
8.
57
Es
ch
er
ic
hi
a 
co
li 
ES
BL
(+
)
1
4.
30
−
−
1
2.
38
−
−
−
−
2
5.
71
St
en
ot
ro
ph
om
on
as
 m
al
to
-
ph
ili
a 
ES
BL
(+
)
−
−
−
−
−
−
−
−
−
−
−
−
En
te
ro
ba
ct
er
 k
ob
ei
 E
SB
L(
+
)
−
−
−
−
−
−
−
−
−
−
−
−
En
tro
ba
ct
er
 a
er
og
en
es
 
ES
BL
(+
)
−
−
−
−
−
−
−
−
−
−
−
−
Pneumonologia i Alergologia Polska 2015, vol. 83, no. 2, pages 101–108 
106 www.pneumonologia.viamedica.pl
Ta
bl
e 
3.
 P
at
ie
nt
s 
tr
ea
te
d 
fo
r c
hr
on
ic
 lu
ng
 d
is
ea
se
s 
(n
 =
 2
02
9 
SP
EC
IM
EN
S)
Th
e 
na
m
e 
of
 th
e 
st
ra
in
20
07
 
n 
=
 4
03
20
08
 
n 
=
 3
69
20
09
 
n 
=
 4
10
20
10
 
n 
=
 4
28
20
11
 
n 
=
 4
19
To
ta
l
(p
er
ce
nt
ag
e)
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
 N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
 N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
N
o 
of
 
in
fe
ct
ed
 
pa
tie
nt
s
%
Ps
eu
do
m
on
as
 a
er
ug
in
os
a
3
13
.0
4
1
4.
20
9
21
.4
2
6
16
.2
1
1
3.
44
20
22
.5
Ac
in
et
ob
ac
te
r b
au
m
an
ii 
ES
BL
(−
)
3
13
.0
4
3
12
.5
0
1
2.
38
−
−
1
3.
44
8
8.
99
St
re
pt
oc
oc
cu
s 
pn
eu
m
on
ia
e
−
−
−
−
5
11
.9
0
5
13
.5
0
3
10
.3
9
13
14
.6
1
En
te
ro
ba
ct
er
 c
lo
ac
ae
 
ES
BL
(+
)
2
8.
70
1
4.
20
3
7.
14
3
8.
10
−
−
9
10
.1
1
Kl
eb
si
el
la
 p
ne
um
on
ia
e 
ES
BL
(+
)
2
8.
70
−
−
2
4.
76
1
2.
70
3
10
.3
9
8
8.
99
St
ap
hy
lo
co
cc
us
 a
ur
eu
s 
M
RS
A
−
−
−
−
1
2.
38
2
5.
40
2
6.
89
5
5.
62
En
te
ro
co
cc
us
 fa
ec
al
is
 
−
−
−
−
2
4.
76
2
5.
40
3
10
.3
9
7
7.
87
Es
ch
er
ic
hi
a 
co
li 
ES
BL
(+
)
−
−
1
4.
20
3
7.
14
3
8.
10
1
3.
44
8
8.
99
St
en
ot
ro
ph
om
on
as
 m
al
to
-
ph
ili
a 
ES
BL
(+
)
−
−
−
−
3
7.
14
1
2.
70
4
13
.7
9
8
8.
99
En
te
ro
ba
ct
er
 k
ob
ei
 E
SB
L(
+
)
−
−
−
−
−
−
−
−
2
6.
89
2
2.
25
En
tro
ba
ct
er
 a
er
og
en
es
 
ES
BL
(+
)
−
−
1
4.
20
−
−
−
−
−
−
1
1.
12
Michał Zieliński et al., Occurrence of alert pathogens in patients hospitalised in the department of lung diseases
107www.pneumonologia.viamedica.pl
In the presented material, in the group of 
patients with chronic diseases of the respiratory 
system and patients with neoplasms, infection 
with A. baumanii occurred more rarely than in-
fection with S. pneumoniae: 8.57% and 14.29%, 
and 8.99% and 14.61% respectively. These results 
correspond with the researches carried out by 
other authors [11, 18, 21]. 
Infection with S. pneumoniae was not found 
in the group of patients qualified for lung trans-
plantation. Presumably, it is related to relatively 
lower resistance of the species to antibiotics [5, 10]. 
Gram (+) cocci — E. faecalis were not found in 
this group of patients either [18].
Among the analysed pathogens, the En-
terobacteriaceae were represented by: E. cloa-
cae ESBL(+), K. pneumoniae ESBL(+), E. kobei 
ESBL(+) and E. coli ESBL(+) present in the mate-
rial in the largest numbers in the group of patients 
with lung neoplastic diseases and in patients with 
chronic pulmonary pathology (31% and 30% re-
spectively). Resistance of Enterobacteriaceae to 
antibiotics is a significant risk factor of prolonged 
hospitalisation [22]. In the analysed material, 
in patients qualified for lung transplantation, 
infections with pathogens from the Enterobac-
teriaceae family constituted 19%. According to 
the literature, K. pneumoniae is a pathogen that 
frequently constitutes an infectious agent in the 
early post-transplant period [23].
According to the agency of the federal govern-
ment of the United States — Centers for Disease 
Control and Prevention — methicillin-resistant 
S. aureus is becoming more and more frequent-
ly recognised infectious agent and the cause of 
deaths. In the United States, infections with 
MRSA cause more deaths than tuberculosis 
and AIDS combined [1]. Next to P. aeruginosa, 
MRSA is the most frequent factor of pneumonia 
and bronchitis among patients who underwent 
immunosuppression due to lung transplantation 
[16, 24], which is in accordance with the results 
of the present study.
The last analysed pathogen was S. maltophil-
ia ESBL(+). This non-fermenting Gram-negative 
bacillus is phylogenetically close to P. aeruginosa 
and it often colonises the airways of the patients 
with chronic lung diseases, in immunosuppres-
sion or treated for neoplasms. COPD patients 
and the persons who repeatedly undergo therapy 
with antibiotics, are at risk of colonisation with 
this bacterium. Its presence is associated with 
prolonged hospitalisation and increased patients’ 
mortality and longer time of mechanical ventila-
tion [6, 25].
prevalence of the remaining pathogens in the 
group was well-balanced. A  lower proportion 
of MRSA (5.6%), compared to the two previous 
groups was observed.
In the analysed groups, resistant strains were 
isolated significantly more often in patients qual-
ified for transplantation (p < 0.01), compared to 
the remaining subjects. The group of patients with 
neoplasms and the group with chronic diseases of 
the respiratory system did not differ significantly 
in respect of proportions of patients infected with 
alert microorganisms. 
Discussion
Alert pathogens made up a significant propor-
tion of bacteria isolated from biological material 
of patients of the department of lung diseases. 
Among the isolated pathogens, P. aeruginosa pre-
vailed. Currently, this pathogen is becoming the 
most frequent cause of infections worldwide, it 
is also changing into more and more resistant to 
the drugs such as quinolones, carbapenems and 
aminiglycosides [1]. P. aeruginosa is an aetiologi-
cal factor of exacerbations of chronic lung diseases 
causing progressive impairment of functioning of 
the respiratory system expressed in lowered forced 
expiratory volume in 1 second (FEV1) [11, 12]. 
Among patients with lowered immunity after lung 
transplantation, this pathogen is an aetiological 
factor of pneumonia, contributing to higher mor-
tality in the early post-transplant period and at 
long-term follow-up. According to the authors 
who conducted the studies in Spain, approxi-
mately 24% of pneumonia cases after lung trans-
plantation is caused by this pathogen [13−16]. 
Moreover, P. aeruginosa is frequently isolated in 
patients with neutropenic fever in the course of 
lung cancer chemotherapy [17, 18].
The consecutive, in respect of frequency, 
pathogen isolated among patients qualified for 
lung transplantation was A. baumanii, which 
occurred comparably as often as P. aeruginosa 
(29% and 35% of infections respectively). The 
results of the published studies have shown that 
the colonisation of the airways with A. baumanii, 
and infection with this pathogen in the post-trans-
plant period, constitute a risk factor of prolonged 
pneumonia in the group of patients after lung 
transplantation, and consequently, lead to pulmo-
nary fibrosis with compensatory hyperinflation 
of a native lung [19, 20]. The recent studies have 
clearly shown that A. baumanii play a crucial 
role in the increase in mortality among patients 
infected with this pathogen [4]. 
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To sum up, alert pathogens constitute a vital 
problem in the group of patients of the depart-
ment of lung diseases. According to our data, 
the group most exposed to infections with these 
bacteria are patients qualified for lung trans-
plantation. For infections influence long-term 
prognosis, their efficient therapy is crucial in all 
groups of patients. It should be emphasised that 
in the analysed material, there were no pathogens 
of most dangerous resistance mechanisms, i.e. 
K. pneumoniae KPC (+) producing beta lact-
amases active to carbapenems, Pseudomonas 
and Acinetobacter MBL(+) strains producing 
metallo beta lactamases or OXA-48 (+) produc-
ing oxacillinases that hydrolise carbapenems or 
vancomycin-resistant Enterococcus strains (VRE) 
or penicillin-resistant pneumococci.
Conclusions
Infection with alert pathogens affected 4% of 
patients hospitalised in the department of lung 
diseases. It occurred significantly more often in 
patients qualified for lung transplantation, com-
pared to the remaining subjects. The pathogen 
that occurred in all study groups was P. aerugi-
nosa (27% of all infections). 
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